immunitoAI Raises $6.1M To Expand AI-Led Antibody Therapeutics Pipeline

The funding comes as the company aims to accelerate the creation of IP-backed antibody therapeutics built without traditional biological sources.

Bengaluru-based biotech startup immunitoAI has raised $6.1 Mn in its Series A round, led by investor and fund manager Ashish Kacholia, to scale its AI-driven antibody development platform.

The funding comes as the company aims to accelerate the creation of IP-backed antibody therapeutics built without traditional biological sources.

The round saw participation from new investors, including 3one4 Capital and AC Ventures, alongside existing backers pi Ventures, Anicut Capital, JITO Incubation & Innovation Foundation, LVX, JJ Family, and a group of angels. According to cofounder and CEO Aridni Shah, Kacholia contributed around $3 Mn, while pi Ventures and Anicut invested $1.25 Mn and $1 Mn, respectively. The remaining amount came from other participating investors.

Founded in 2020 by Shah and Trisha Chatterjee, immunitoAI builds antibody therapeutics using generative AI models that design sequences for any target antigen. The company claims its technology compresses antibody development timelines from the standard 4–5 years to 11–12 months, significantly speeding up early discovery for conditions including cancer and infectious diseases.

The startup validates these AI-generated antibody sequences in its own wet lab and currently operates in the pre-revenue stage. Pharma companies remain its primary target customers as the platform moves toward commercial deployment.

Before this round, immunitoAI had raised about $1.8 Mn in seed and bridge funding, which helped make its technology trial-ready. The newly secured capital will now support the development of proprietary antibodies that will form part of the company’s IP portfolio.

Shah outlined three revenue pathways: selling fully developed antibodies or IP to pharma companies, creating custom antibodies on demand, and eventually developing end-to-end drugs as a standalone biotech manufacturer. The startup estimates that a fully customised antibody could command $300 Mn-plus along with royalties, while ready IP assets could be priced even higher.

The fundraiser comes amid growing adoption of GenAI across India’s healthcare and pharmaceutical ecosystems, from robotic surgery to drug discovery workflows. Startups including Morphle Labs and CrisprBits also announced fresh capital raises today, highlighting rising investor interest in AI-first biotech innovation.

Stay tuned for more such updates on Digital Health News